Clinical trials: Primary Lateral Sclerosis
Tetraplegia/Tetraparesis, Quadriplegia
Precise Robotically IMplanted Brain-Computer InterfacE
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or…
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
- Trial name
- PRIME (NCT06429735)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Neuralink Corp
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT07369076
- Testing
- NB-4746 High dose, NB-4746 Low dose, NB-4746 (Dose TBD)
- Where
- 12 sites in Australia, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Nura Bio
Amyotrophic Lateral Sclerosis
Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis
The purpose of the study is to evaluate the safety of combining phospholipids with medicinal plants for treatment of patients with amyotrophic lateral sclerosis (ALS)
- Trial name
- ALS-PHL (NCT02588807)
- Testing
- Spirit1
- Where
- Israel
- Sponsor
- Herb Spirit
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Amyotrophic Lateral Sclerosis
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
This is a phase I, multicentre randomised, double-blind, placebo-controlled trial to assess the safety and tolerability of continuous i.c.v.
- Trial name
- NCT01999803
- Testing
- sNN0029
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 15 people
- Sponsor
- Newron Sweden AB
Amyotrophic Lateral Sclerosis (ALS)
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02588677
- Testing
- Masitinib (4.5), Riluzole, Masitinib (3.0)
- Where
- Spain
- Volunteers
- 394 people
- Sponsor
- AB Science
Japanese Patients With ALS
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Amyotrophic Lateral Sclerosis Patients with gastrostomy
- Trial name
- NCT04254913
- Testing
- MT-1186
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.
- Trial name
- ROSF (NCT03679975)
- Testing
- Riluzole Oral Soluble film (ROSF) 50 mg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Aquestive Therapeutics
ALS, Amyotrophic Lateral Sclerosis
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study.
- Trial name
- NCT04948645
- Testing
- Fosigotifator
- Where
- 14 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- AbbVie
Amyotrophic Lateral Sclerosis
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
The study is to determine the feasibility, safety, toxicity, and maximum tolerated (safe) dose of human spinal derived neural stem cell transplantation for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01730716
- Testing
- Human spinal cord stem cell implantation
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuralstem Inc.
Amyotrophic Lateral Sclerosis
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
- Trial name
- CARDINALS (NCT05349721)
- Testing
- PTC857
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 336 people
- Sponsor
- PTC Therapeutics
ALS
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
- Trial name
- ALS (NCT00696332)
- Testing
- Talampanel
- Where
- 24 sites in United States, Belgium and 8 more
- Volunteers
- 559 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
- Trial name
- COURAGE-ALS (NCT04944784)
- Testing
- Reldesemtiv
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 489 people
- Sponsor
- Cytokinetics
Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury
Research on Wireless Brain Implant System for General Control of External Devices
The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive…
- Conditions
- Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury, Brainstem Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- RISE (NCT06829212)
- Testing
- WRS
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai StairMed Technology Co., Ltd.
Amyotrophic Lateral Sclerosis
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002.
- Trial name
- NeurALS (NCT07660614)
- Testing
- LTX-002
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 56 people
- Sponsor
- Leal Therapeutics, Inc